Scope and US Patent Landscape for 9,545,426 (Amisulpride for Preventing Post-Operative Nausea and Vomiting)
US Patent 9,545,426 claims a dosing-based, route-agnostic method for prevention and/or treatment of post-operative nausea and vomiting (PONV) using amisulpride in a defined 1 mg to 20 mg range, with multiple dependent claim hooks covering emetogenic co-administration (including morphine), formulation/salt scope, combination therapy (including 5-HT3 antagonist/ondansetron and dexamethasone), human use, surgery and anesthetic context, and multiple administration routes.
The practical infringement and freedom-to-operate (FTO) risk is concentrated in products or clinical protocols that use amisulpride at clinically specific low doses (sub-antipsychotic range) to manage PONV, especially where the regimen falls within the claimed dose band and the product is used in surgical PONV settings.
What does US Patent 9,545,426 claim for post-operative nausea and vomiting?
Core independent claim (Claim 1):
A method to prevent and/or treat PONV by administering amisulpride to a subject undergoing a surgical procedure, at a dose of 1 mg to 20 mg.
Key claim 1 scope levers
- Indication: “prevention and/or treatment of post-operative nausea and vomiting”
- Target population: “subject of a surgical procedure and in need of such prevention and/or treatment”
- Drug identity: amisulpride (not restricted to base vs salt in the independent claim)
- Dose range: 1 mg to 20 mg
- No route limitation in Claim 1: route options are introduced in dependent claims
Immediate enforceability signal
- The independent claim is broad on route and on specific surgery types (those appear only in dependent claims).
- The independent claim is narrowed primarily by (i) PONV surgical context and (ii) the 1 mg to 20 mg dosing window.
How broad is the 1 mg to 20 mg dose window, practically?
A 1–20 mg band is large enough to cover multiple clinical regimens (single-dose or repeat dosing depending on clinical protocols), but it is still narrow compared with standard antipsychotic dosing regimes. For patent scope analysis, this band is the central question for FTO:
- If amisulpride is used below 1 mg for PONV, Claim 1 may be avoided on dose.
- If used above 20 mg, Claim 1 may be avoided on dose, though dependent claims may introduce other constraints depending on how prosecution and specification define dosing.
Does Claim 1 require a particular administration route?
No. Claim 1 is route-agnostic. Dependent claims add specific routes:
- Intravenous (Claim 17)
- Intramuscular (Claim 18)
- Subcutaneous (Claim 19)
- Oral (Claim 20)
- Topical (Claim 21)
- Rectal (Claim 22)
- Intranasal (Claim 23)
- Transdermal (Claim 24)
This makes the patent difficult to design around through route selection alone if the dose and indication are maintained.
Does the patent cover humans specifically?
Yes via dependent Claim 5:
- “wherein the subject is a human.”
If a product is only tested or used in non-human contexts, that may affect claim mapping, but clinical practice and likely infringement theories target human administration for PONV.
Which dependent claims expand the method scope for co-therapy and clinical context?
What if the surgical patient is also given an emetogenic agent? (Claims 2–4)
Claim 2 adds co-administration of an emetogenic agent.
Claim 3 limits that emetogenic agent to an opiate.
Claim 4 specifies morphine.
Practical interpretation for coverage
- These are narrower dependent claim layers, but they are strategically important: many perioperative PONV protocols use opioids.
- If an infringing regimen uses amisulpride 1–20 mg for PONV while the patient receives morphine (or opioid regimens that map to morphine), the claim set is strengthened by Claim 2–4 dependencies.
How does combination therapy with anti-emetics broaden coverage? (Claims 7–10)
Claim 7: amisulpride plus “another anti-emetic drug.”
Claim 8: the other anti-emetic is a 5-HT3 antagonist.
Claim 9: the 5-HT3 antagonist is ondansetron.
Claim 10: amisulpride is administered with dexamethasone.
Design-around implications
- Hospitals often use multimodal PONV prophylaxis (ondansetron, dexamethasone).
- Combining those with amisulpride in the claimed dose band can move a clinician from potentially Claim 1-only exposure into multiple dependent claim layers, increasing litigation leverage for the patent holder.
Does the patent require specific anesthetic or surgery types? (Claims 15–16)
Claim 15: subject has “received an anesthetic.”
Claim 16: surgical procedure chosen from:
- eye or ear procedures
- laparoscopic cholecystectomy
- hysterectomy
- breast surgery
- abdominal surgery
- gynecological surgery
These dependent claims matter in litigation where the patentee can show a direct match to common perioperative categories, but they are not prerequisites for Claim 1.
What formulation and stereochemical scope is covered?
Salt and stereochemistry
- Claim 6: amisulpride in an “acceptable pharmaceutical salt.”
- Claim 25: amisulpride is (S—)-amisulpride.
Scope impact
- Claim 6 captures formulation strategies that use a salt form for stability, solubility, or administration.
- Claim 25 captures stereochemical targeting. If the market uses specific enantiomers or enriched stereochemistry, Claim 25 becomes a critical mapping point.
Other dose subranges and numeric capture (Claims 11–14)
Dependent claims specify:
- 2.5 mg to 20 mg (Claim 11)
- 2.5 mg (Claim 12)
- 5 mg (Claim 13)
- 20 mg (Claim 14)
Litigation leverage
- If clinical practice uses a standard dosing protocol (for example 5 mg single dose), the dependent claims can be asserted even if broader dose window arguments are contested.
- These dependent claims reduce ambiguity: exact dosing protocols can be matched to single numeric claims.
How strong is the patent estate likely to be for this specific use?
Based solely on the claim set provided, the patent appears to be built for:
- Broad method coverage (Claim 1: dose band + PONV surgical context)
- Many “common clinical scenario” hooks (opioids/morphine; ondansetron; dexamethasone; anesthetic context; multiple surgery categories)
- Multiple route options (including injectable and non-injectable forms)
- Formulation and stereochemistry scope (salt form and S-enantiomer)
This architecture typically yields strong claim coverage across real-world practice, where clinicians select multimodal prophylaxis and opioids are present.
Does US 9,545,426 function as a “composition” or “method-of-use” patent?
It is a method-of-use patent because all listed claims are framed as a method of prevention and/or treatment via administering amisulpride under specified conditions and doses. There is no direct claim in your list that covers an independent composition per se.
Commercial implication
- Generic/brand product differentiation will not eliminate infringement risk if the generic label or off-label use instructions/clinical uptake align with the claimed administration method.
What is the likely US infringement theory if a generic amisulpride is used for PONV?
If a generic amisulpride product is substituted into a clinical protocol that matches Claim 1 (and related dependent claims), exposure can include:
- Direct infringement by prescribing/dispensing/administration teams (depending on the factual and legal pathway in the specific litigation posture).
- Induced infringement theories if marketing or clinical protocols promote the claimed method.
- Contributory infringement is possible when the product is used specifically for the claimed PONV method.
From a technical mapping standpoint, the key issue for any competitor is whether their clinical protocol administers amisulpride within 1–20 mg for surgical PONV prevention/treatment, and whether co-therapies and patient contexts match dependent claims.
Patent landscape: what other US patents typically surround this type of claim?
Without the application family data, assignees, and cited references for 9,545,426, a complete landscape mapping (grant/imminent expiration, continuations, related families) cannot be reconstructed from claim text alone. The landscape below therefore focuses on claim-adjacent categories that commonly coexist with this kind of method-of-use patent, which you should treat as issue-spotting categories for diligence.
Adjacent patent families likely to be relevant
-
Amisulpride in PONV prophylaxis/treatment
- Methods varying dose (lower vs higher)
- Specific routes (IV vs oral vs rectal)
- Patient selection criteria (opioid-induced nausea, high-risk PONV scoring)
-
Amisulpride combinations for PONV
- With 5-HT3 antagonists such as ondansetron
- With corticosteroids such as dexamethasone
- With other anti-emetics (NK1 antagonists, droperidol, etc.)
-
Formulation or delivery patents
- Salt forms, enantiomer-enriched amisulpride
- Novel delivery vehicles to achieve rapid onset in perioperative window
-
Perioperative opioid-emetogenic agent dependence
- If claims are built around morphine or opioids, there may be separate patents tied to opioid-associated PONV pathways.
Key claim-to-protocol mapping matrix (for infringement/FTO triage)
| Scenario element |
Claim coverage |
Coverage trigger |
| Surgical PONV prevention/treatment |
Claim 1 |
Amisulpride administered to surgical patient needing PONV prevention/treatment |
| Dose band |
Claim 1 |
1 mg to 20 mg |
| Standard single dose 5 mg |
Claim 13 |
Administration at 5 mg |
| Lower single dose 2.5 mg |
Claim 12 |
Administration at 2.5 mg |
| High end 20 mg |
Claim 14 |
Administration at 20 mg |
| Dose within 2.5–20 |
Claim 11 |
Administration between 2.5 mg and 20 mg |
| Opioid co-administration |
Claim 2–4 |
Emotogenic agent is an opiate; morphine if Claim 4 asserted |
| 5-HT3 combination |
Claim 7–9 |
Another anti-emetic is 5-HT3 antagonist; ondansetron if Claim 9 asserted |
| Dexamethasone combination |
Claim 10 |
Amisulpride + dexamethasone |
| Human subjects |
Claim 5 |
Subject is human |
| Anesthesia context |
Claim 15 |
Subject received an anesthetic |
| Procedure types |
Claim 16 |
Eye/ear; laparoscopic cholecystectomy; hysterectomy; breast/abdominal/gynecological surgery |
| Routes |
Claim 17–24 |
IV, IM, SC, oral, topical, rectal, intranasal, transdermal |
| Salt forms |
Claim 6 |
Acceptable pharmaceutical salt |
| S-enantiomer |
Claim 25 |
(S—)-amisulpride |
When does this patent most matter commercially?
This patent is most commercially sensitive where:
- Amisulpride is used specifically for PONV prophylaxis/treatment post-operatively.
- Dosing aligns with 1–20 mg, especially 2.5 mg, 5 mg, and 20 mg.
- Protocols commonly include opioids, ondansetron, and dexamethasone.
Competitors seeking market entry via product substitution should assess not just the active ingredient, but the protocol used in clinical practice and any label or promotional positioning that could be construed as promoting the claimed method.
Key Takeaways
- US 9,545,426 is a method-of-use patent with a broad independent claim covering amisulpride 1–20 mg administered for surgical PONV prevention and/or treatment.
- The claim set is reinforced by dependent claims that map closely to real perioperative PONV regimens: opioids/morphine, ondansetron (5-HT3), dexamethasone, anesthetic exposure, and common surgery categories.
- Route is extensively covered in dependent claims, so changing administration route alone is unlikely to avoid risk if the dose band and PONV use remain.
- Numeric dependent claims (2.5 mg, 5 mg, 20 mg) are litigation-friendly anchors for matching specific protocols.
- Salt and stereochemical dependent claims (acceptable salts; (S—)-amisulpride) broaden formulation and product-identity coverage.
FAQs
-
If a competitor uses amisulpride 0.5 mg for PONV, does it avoid Claim 1?
Claim 1 requires 1 mg to 20 mg, so 0.5 mg falls outside the stated dose band.
-
Does giving amisulpride for PONV off-label after surgery infringe if the dose matches?
The claims are method-based and focus on administration for surgical PONV prevention/treatment at the claimed dose; off-label status does not negate the claim elements.
-
Is ondansetron required for infringement of the independent claim?
No. Ondansetron appears only in dependent claims (Claims 7–9).
-
Can infringement occur with non-injectable delivery (e.g., oral or intranasal)?
Yes. Dependent claims cover oral, rectal, intranasal, transdermal, and topical routes.
-
What single fact most quickly determines whether a protocol is inside the claim set?
Whether the protocol administers amisulpride 1–20 mg for surgical PONV prevention/treatment.
